FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020907114> ?p ?o ?g. }

• W2020907114 endingPage "642" @default.
• W2020907114 startingPage "642" @default.
• W2020907114 abstract "Given the limitations in health care resources, quality-of-life measures for interventions have gained importance.To determine whether vision-related quality-of-life outcomes were different between the natamycin and voriconazole treatment arms in the Mycotic Ulcer Treatment Trial I, as measured by an Indian Vision Function Questionnaire.Secondary analysis (performed October 11-25, 2014) of a double-masked, multicenter, randomized, active comparator-controlled, clinical trial at multiple locations of the Aravind Eye Care System in South India that enrolled patients with culture- or smear-positive filamentous fungal corneal ulcers who had a baseline visual acuity of 20/40 to 20/400 (logMAR of 0.3-1.3).Study participants were randomly assigned to topical voriconazole, 1%, or topical natamycin, 5%.Subscale score on the Indian Vision Function Questionnaire from each of the 4 subscales (mobility, activity limitation, psychosocial impact, and visual function) at 3 months.A total of 323 patients were enrolled in the trial, and 292 (90.4%) completed the Indian Vision Function Questionnaire at 3 months. The majority of study participants had subscale scores consistent with excellent function. After adjusting for baseline visual acuity and organism, we found that study participants in the natamycin-treated group scored, on average, 4.3 points (95% CI, 0.1-8.5) higher than study participants in the voriconazole-treated group (P = .046). In subgroup analyses looking at ulcers caused by Fusarium species and adjusting for baseline best spectacle-corrected visual acuity, the natamycin-treated group scored 8.4 points (95% CI, 1.9-14.9) higher than the voriconazole-treated group (P = .01). Differences in quality of life were not detected for patients with Aspergillus or other non-Fusarium species as the causative organism (1.5 points [95% CI, -3.9 to 6.9]; P = .52).We found evidence of improvement in vision-related quality of life among patients with fungal ulcers who were randomly assigned to natamycin compared with those randomly assigned to voriconazole, and especially among patients with Fusarium species as the causative organism. Incorporation of quality-of-life measures in clinical trials is important to fully evaluate the effect of the studied interventions.clinicaltrials.gov Identifier:NCT00996736." @default.
• W2020907114 created "2016-06-24" @default.
• W2020907114 creator A5004140941 @default.
• W2020907114 creator A5004723861 @default.
• W2020907114 creator A5009715006 @default.
• W2020907114 creator A5020482003 @default.
• W2020907114 creator A5049858913 @default.
• W2020907114 creator A5061350970 @default.
• W2020907114 creator A5062936310 @default.
• W2020907114 creator A5069369290 @default.
• W2020907114 creator A5069890349 @default.
• W2020907114 creator A5075952432 @default.
• W2020907114 creator A5080095497 @default.
• W2020907114 creator A5084428982 @default.
• W2020907114 creator A5087014948 @default.
• W2020907114 creator A5087875655 @default.
• W2020907114 creator A5091117608 @default.
• W2020907114 date "2015-06-01" @default.
• W2020907114 modified "2023-09-27" @default.
• W2020907114 title "Vision-Related Quality-of-Life Outcomes in the Mycotic Ulcer Treatment Trial I" @default.
• W2020907114 cites W1965983471 @default.
• W2020907114 cites W1971302473 @default.
• W2020907114 cites W1975905305 @default.
• W2020907114 cites W1976552292 @default.
• W2020907114 cites W1991534463 @default.
• W2020907114 cites W2001276323 @default.
• W2020907114 cites W2026005354 @default.
• W2020907114 cites W2027463798 @default.
• W2020907114 cites W2030729228 @default.
• W2020907114 cites W2043591479 @default.
• W2020907114 cites W2067239339 @default.
• W2020907114 cites W2083996369 @default.
• W2020907114 cites W2085451945 @default.
• W2020907114 cites W2085483866 @default.
• W2020907114 cites W2096257972 @default.
• W2020907114 cites W2117322871 @default.
• W2020907114 cites W2562222275 @default.
• W2020907114 doi "https://doi.org/10.1001/jamaophthalmol.2015.0319" @default.
• W2020907114 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4962866" @default.
• W2020907114 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25764482" @default.
• W2020907114 hasPublicationYear "2015" @default.
• W2020907114 type Work @default.
• W2020907114 sameAs 2020907114 @default.
• W2020907114 citedByCount "8" @default.
• W2020907114 countsByYear W20209071142015 @default.
• W2020907114 countsByYear W20209071142018 @default.
• W2020907114 countsByYear W20209071142019 @default.
• W2020907114 countsByYear W20209071142020 @default.
• W2020907114 countsByYear W20209071142021 @default.
• W2020907114 crossrefType "journal-article" @default.
• W2020907114 hasAuthorship W2020907114A5004140941 @default.
• W2020907114 hasAuthorship W2020907114A5004723861 @default.
• W2020907114 hasAuthorship W2020907114A5009715006 @default.
• W2020907114 hasAuthorship W2020907114A5020482003 @default.
• W2020907114 hasAuthorship W2020907114A5049858913 @default.
• W2020907114 hasAuthorship W2020907114A5061350970 @default.
• W2020907114 hasAuthorship W2020907114A5062936310 @default.
• W2020907114 hasAuthorship W2020907114A5069369290 @default.
• W2020907114 hasAuthorship W2020907114A5069890349 @default.
• W2020907114 hasAuthorship W2020907114A5075952432 @default.
• W2020907114 hasAuthorship W2020907114A5080095497 @default.
• W2020907114 hasAuthorship W2020907114A5084428982 @default.
• W2020907114 hasAuthorship W2020907114A5087014948 @default.
• W2020907114 hasAuthorship W2020907114A5087875655 @default.
• W2020907114 hasAuthorship W2020907114A5091117608 @default.
• W2020907114 hasBestOaLocation W20209071142 @default.
• W2020907114 hasConcept C118487528 @default.
• W2020907114 hasConcept C118552586 @default.
• W2020907114 hasConcept C126322002 @default.
• W2020907114 hasConcept C142724271 @default.
• W2020907114 hasConcept C150966472 @default.
• W2020907114 hasConcept C159110408 @default.
• W2020907114 hasConcept C16005928 @default.
• W2020907114 hasConcept C168563851 @default.
• W2020907114 hasConcept C2776079991 @default.
• W2020907114 hasConcept C2778257484 @default.
• W2020907114 hasConcept C2778560704 @default.
• W2020907114 hasConcept C2779117757 @default.
• W2020907114 hasConcept C2779548794 @default.
• W2020907114 hasConcept C2779951463 @default.
• W2020907114 hasConcept C2780690907 @default.
• W2020907114 hasConcept C535046627 @default.
• W2020907114 hasConcept C71924100 @default.
• W2020907114 hasConceptScore W2020907114C118487528 @default.
• W2020907114 hasConceptScore W2020907114C118552586 @default.
• W2020907114 hasConceptScore W2020907114C126322002 @default.
• W2020907114 hasConceptScore W2020907114C142724271 @default.
• W2020907114 hasConceptScore W2020907114C150966472 @default.
• W2020907114 hasConceptScore W2020907114C159110408 @default.
• W2020907114 hasConceptScore W2020907114C16005928 @default.
• W2020907114 hasConceptScore W2020907114C168563851 @default.
• W2020907114 hasConceptScore W2020907114C2776079991 @default.
• W2020907114 hasConceptScore W2020907114C2778257484 @default.
• W2020907114 hasConceptScore W2020907114C2778560704 @default.
• W2020907114 hasConceptScore W2020907114C2779117757 @default.
• W2020907114 hasConceptScore W2020907114C2779548794 @default.
• W2020907114 hasConceptScore W2020907114C2779951463 @default.
• W2020907114 hasConceptScore W2020907114C2780690907 @default.

• next